Trial Profile
Phase I/II Trial of MOC31PE Immunotoxin in Peritoneal Carcinomatosis From Colorectal Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody moc 31 PE conjugate (Primary) ; Monoclonal antibody moc 31 PE conjugate (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms ImmunoPeCa
- 24 May 2017 Status changed from recruiting to completed.
- 10 May 2016 New trial record
- 20 Apr 2016 Results of ImmunoPeCa phase I study (n=12) presented at the 107th Annual Meeting of the American Association for Cancer Research